MRKR — Trading Ideas on TradingView

MKR : THE NEW TREND TO ABOVE 1K MKR Seem to be on way to higher trend, as its on 4H range building new volume can this coin enter 1k trend it will get more updates. At this moment its one of the best coins that can have increase for coming low time frame.

MRK Analysis - Rising Wedge Rising Wedge and Ascending H&S, leading to a break down over a weak uptrend line down to the .618 Fibonacci line Rising wedges and H&S patterns are both considered bearish Attaching my thoughts about the ascending H&S

MRKR (Marker Therapeutics, Inc): Something with huge Risk:Reward Hello folks MRKR (Marker Therapeutics, Inc) still sleeping but its worth to thinking about. Why? MARKER THERAPEUTICS is a clinical-stage immuno-oncology c NASDAQ:MRKR ompany, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Company news are incredibly good and forecast of stock is very bright because they find to But this symbol needs some confident from traders. Today's price is interesting for value investors. MRKR is one of the under-radar stocks. we love it! Now what? We added more to this symbol and details are below: Target 1: 5.95 USD (%160 Reward) Target 2: 7.90 USD (%250 Reward) Stop Loss: 2.00 USD (%10 Risk) Entry Type: Buy Limit Entry Point: 2.25 Risk Reward Ratio: 1:16 & 1:24 Stay safe and refer us to your friends and follow us for new ideas. More data for who like to read: "We are pleased with the results of the safety lead-in portion of the trial, in which all six patients met the safety endpoints following infusion of our MultiTAA-specific T cell therapy," said Mythili Koneru, M.D., Ph.D., Chief Medical Officer of Marker Therapeutics. "We are currently enrolling patients in the main portion of our first Company-sponsored trial and continue to activate clinical sites across the U.S. We are looking forward to further advancing MT-401 in this disease setting. Despite recent advances in how hematological malignancies are treated, patients remain in urgent need of new therapeutic options." About Marker's Phase 2 AML Post-Transplant Study The multicenter Phase 2 AML study is evaluating the clinical efficacy of MT-401 in patients with AML following an allogeneic stem-cell transplant in both the adjuvant and active disease setting. In the adjuvant setting, approximately 120 patients will be randomized 1:1 to either MT-401 at 90 days post-transplant versus standard-of-care observation, while approximately 40 patients with active disease will receive MT-401 as part of the single-arm group. The primary objectives of the trial are to evaluate relapse-free survival in the adjuvant group and determine the complete remission rate and duration of complete remission in active disease patients. Additional objectives include, for the adjuvant group, overall survival and graft-versus-host disease relapse-free survival while additional objectives for the active disease group include overall response rate, duration of response, progression-free survival and overall survival. In April 2020, the FDA granted Orphan Drug designation to MT-401 for the treatment of patients with AML following allogeneic stem cell transplant. Forward-Looking Statements This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401; and the overall market opportunity for our product candidates. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at sec gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

MRKR (NASDAQ) - Gap should be closed Greetings Humbled, we would like to thanks for your support who has already liked, commented and followed us. Your support, strengthens us, to help in analyzing the market. If you have any questions, feel free to send us message (inbox). Pra Trading : - Please care for Money Management - Have a good psychology - Do not be hurry to open position and do not do nothing if u see opportunity - Evaluate and upgrade your trading plan Execution Strategy : - Know what you want to buy, see the Fundamental - Decide that you are on investing or speculating - Consider what your strategy based on Investing/Speculating - Make Road Map Of Your Trading Plan - Decide a. Entry strategy b. Cut loss c. Target of Profit Post Trading : a. Do not be sad if you loss or do not be very happy if you win b. Just become a normal without emotion, Do not put emotion into your trading c. Evaluate your trading d. Keep on Learning e. Be Humble Idea : MRKR (NASDAQ) - Gap should be closed

$MRKR Saw this call on wallstreetbets yesterday and it looks like a very interesting call. Read more here: www.reddit.com Summary for TLDR: Their CEO guys bought a ton of stocks recently and they are into experimental cancer drugs. So maybe there is something on the horizon. If you zoom out on the monthly it has an obscene dilution similar to VISL. Go apes go.

Stock to watch: TapImmune Inc. common stock (MRKR) - risk-trade NASDAQ:MRKR A risky yet interesting trade: Buy/Sell Zones is in the green line, but we should consider it as a pullback - the overall downtrend + bearish momentum. I may consider Short up 0.786 Fib (where we can see another pullback) but could dip even lower. Invalidation: closing above 1.75 on higher timeframes (12H, 1D). Disclaimer: This article should not be considered as financial or investment advice. Trading digital assets involve risk and may resolve in the loss of your capital. Always be sure to understand the amount of risk involved and do your research before taking any trading/investment steps.

Potential Reversal Marker Therapeutics MRKR Entered MRKR at $4.01 on Friday (11/1/19) and am monitoring for a sustained trend reversal. Watching for SP to bounce off $4.10, or if that does not hold, $4.01. If it does not reverse here I think it'll consolidate between $3.83 and $4.32. A reversal would coincide with a run-up into Q3 earnings which should be sometime this month and phase 2 data in Ovarian Cancer expected this quarter. Closing over $4.32 would be a good confirmation of a trend reversal. RSI and CCI on the daily support the stock is building momentum IMO.

MARKER THERAPEUTICS INC - NASDAQ: $MRKR Consolidates After recapturing its 200 DMA a week ago on meaningful volume, the shares of MARKER THERAPEUTICS INC - NASDAQ;MRKR have found themselves consolidating the recent move in a constructive and orderly manner as is evidenced in the Daily chart above. With the stock now trading above all of its important moving averages 20/50/200 DMA's, the technical posture is favorable for MRKR . In addition, there are potential catalysts for the stock forthcoming in the weeks ahead, in particular, Marker Therapeutics is to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma on July 20, 2019. finance.yahoo.com Thus, moving forward, both investors/traders may want to continue to monitor the action closely and should MRKR be capable of going topside of the $8.15 figure at any point in the days ahead, we suspect that the stock may just have eyes for the $9 - $10 zone once the present consolidation runs its course.